We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+31.1%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$901M
AUM Growth
+$18M
Cap. Flow
-$112M
Cap. Flow %
-12.47%
Top 10 Hldgs %
81.99%
Holding
29
New
3
Increased
5
Reduced
1
Closed
5

Top Buys

Rank Stock Value
1
PTCT icon
PTC Therapeutics
PTCT
+$10.6M
2
DBVT
DBV Technologies
DBVT
+$8.84M
3
MDCO
Medicines Co
MDCO
+$5.65M
4
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$5.29M
5
AMRN
Amarin Corp
AMRN
+$4.91M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$49.6M
2
VKTX icon
Viking Therapeutics
VKTX
+$35.6M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$26.6M
4
MGNX icon
MacroGenics
MGNX
+$25.7M
5
ONCT
Oncternal Therapeutics, Inc. Common Stock
ONCT
+$20.1M

Sector Composition

Rank Sector Weight
1 Healthcare 95.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SLDB icon
1
Solid Biosciences
SLDB
$794M
$136M 15.09%
192,107
+6,774
+4% +$4.26M
ONC
2
BeOne Medicines Ltd
ONC
$32.8B
$108M 12.04%
630,000
– –
PTCT icon
3
PTC Therapeutics
PTCT
$5.64B
$101M 11.24%
2,155,000
+255,000
+13% +$10.6M
WVE icon
4
Wave Life Sciences
WVE
$1.09B
$79.5M 8.83%
1,590,600
– –
MRTX
5
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$73.7M 8.18%
1,565,560
– –
ESPR
6
DELISTED
Esperion Therapeutics
ESPR
$61M 6.77%
1,375,000
– –
ODT
7
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$54.9M 6.09%
2,826,938
– –
RCKT icon
8
Rocket Pharmaceuticals
RCKT
$340M
$48.4M 5.37%
1,966,051
– –
MDCO
9
DELISTED
Medicines Co
MDCO
$41.9M 4.65%
1,400,000
+150,000
+12% +$5.65M
DBVT
10
DBV Technologies
DBVT
$799M
$33.7M 3.74%
150,000
+43,500
+41% +$8.84M
RETA
11
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$32.7M 3.63%
400,000
+75,000
+23% +$5.29M
KNSA icon
12
Kiniksa Pharmaceuticals
KNSA
$5.8B
$29.9M 3.32%
1,172,700
– –
CBAY
13
DELISTED
Cymabay Therapeutics
CBAY
$23.2M 2.57%
2,094,000
– –
AMRN
14
Amarin Corp
AMRN
$299M
$21.2M 2.35%
+65,000
New +$4.91M
KURA icon
15
Kura Oncology
KURA
$800M
$14.8M 1.64%
844,789
– –
LITS
16
Lite Strategy Inc
LITS
$32.8M
$12.6M 1.39%
145,655
– –
RIGL icon
17
Rigel Pharmaceuticals
RIGL
$681M
$7.45M 0.83%
232,190
– –
KALV
18
DELISTED
KalVista Pharmaceuticals
KALV
$4.42M 0.49%
+200,000
New +$2.7M
VIRX
19
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$4.25M 0.47%
60,714
– –
RGLS
20
DELISTED
Regulus Therapeutics
RGLS
$4.03M 0.45%
14,148
– –
XENE icon
21
Xenon Pharmaceuticals
XENE
$6.06B
$3.96M 0.44%
+300,000
New +$3.48M
BLPH
22
DELISTED
Bellerophon Therapeutics, Inc.
BLPH
$1.6M 0.18%
98,810
-25,000
-20% -$594K
ELDN icon
23
Eledon Pharmaceuticals
ELDN
$261M
$1.51M 0.17%
18,021
– –
SNDX icon
24
Syndax Pharmaceuticals
SNDX
$1.69B
$808K 0.09%
100,000
– –
MDGL icon
25
Madrigal Pharmaceuticals
MDGL
$10.8B
– –
-95,000
Closed -$26.6M
1
2

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q3 2018 Portfolio in Review

As of Q3 2018, Boxer Capital held 29 positions worth $901M, up 2% from $883M the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Boxer Capital withdrew a net $112M in Q3 2018, closing 5 positions and reducing 1 holding. Its most notable exit was Sarepta Therapeutics, an estimated $49.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 94% a quarter earlier.

Against the trend, Boxer Capital opened a new position in Amarin Corp worth $21.2M.

  • Boxer Capital's largest Q3 2018 buy was Amarin Corp: 65,000 shares worth $21.2M.
  • Boxer Capital added most to PTC Therapeutics in Q3 2018, an estimated $10.6M increase.
  • Boxer Capital's biggest Q3 2018 reduction was Bellerophon Therapeutics, Inc., cutting an estimated $594K.
  • Boxer Capital fully exited Sarepta Therapeutics in Q3 2018, selling an estimated $49.6M.
  • Boxer Capital's ten largest holdings make up 82% of its $901M portfolio in Q3 2018.
  • Boxer Capital opened 3 new positions and closed 5 in Q3 2018.
  • Boxer Capital's portfolio value rose 2% quarter-over-quarter to $901M.

Based on Boxer Capital's 13F filing for Q3 2018, filed 14 Nov 2018.